DICE THERAPEUTICS
DICE Therapeutics is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas... . The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.
DICE THERAPEUTICS
Social Links:
Industry:
Biotechnology Medical Medical Device
Founded:
2013-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.dicetherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
(650) 566-1402
Email Addresses:
[email protected]
Total Funding:
187.38 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default LetsEncrypt IPv6 AJAX Libraries API COVID-19 JQuery CDN CloudFront New Relic
Similar Organizations
Black Diamond Therapeutics
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule.
BlueLight Therapeutics
BlueLight Therapeutics uses a proprietary structure-based platform to discover small molecules against difficult-to-drug targets.
CODA Biotherapeutics
CODA Biotherapeutics develops a chemogenetic platform designed to modulate neuronal activity.
Humacyte
Humacyte develops products for vascular diseases and replacement of anatomical conduits.
Intarcia Therapeutics
Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
OxSonics Therapeutics
OxSonics® Therapeutics’ proprietary drug delivery platform technology, SonoTran®
Tarsa Therapeutics
Tarsa Therapeutics develops an oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Eventide
Eventide investment in Series C - Dice Therapeutics
Logos Capital
Logos Capital investment in Series C - Dice Therapeutics
Soleus Capital
Soleus Capital investment in Series C - Dice Therapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Series C - Dice Therapeutics
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series C - Dice Therapeutics
Asymmetry Capital Management
Asymmetry Capital Management investment in Series C - Dice Therapeutics
Driehaus Capital Management
Driehaus Capital Management investment in Series C - Dice Therapeutics
Northpond Ventures
Northpond Ventures investment in Series C - Dice Therapeutics
Sands Capital Ventures
Sands Capital Ventures investment in Series C - Dice Therapeutics
Deep Track Capital
Deep Track Capital investment in Series C - Dice Therapeutics
Official Site Inspections
http://www.dicetherapeutics.com Semrush global rank: 722.62 K Semrush visits lastest month: 56.89 K
- Host name: 43.142.223.35.bc.googleusercontent.com
- IP address: 35.223.142.43
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Dice Therapeutics"
DICE THERAPEUTICS
We design and develop innovative oral medicines against biologically validated targets in immunology for the treatment of chronic autoimmune and inflammatory diseases. We are …See details»
Dice Therapeutics - Crunchbase Company Profile
Contact Email [email protected]. Phone Number (650) 566-1402. DICE Therapeutics is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to …See details»
J. Kevin Judice, Ph.D. - DICE THERAPEUTICS
Kevin Judice currently serves as the co-founder and CEO of DICE Therapeutics. Prior to DICE, he co-founded Achaogen, Inc., where, as the first employee, he was the chief scientific officer and CEO. During his seven-year tenure at …See details»
DICE Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Www.dicetherapeutics.com. Public Company | Subsidiary Company | 2013 | California, United States | 50-100 | NASDAQ: DICE | www.dicetherapeutics.com. Last update 01 Nov 2024. …See details»
Lilly Completes Acquisition of DICE Therapeutics
INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: …See details»
DICE Therapeutics Company Profile 2024: Valuation, Investors ...
DICE Therapeutics General Information Description. DICE Therapeutics Inc is a biopharmaceutical company leveraging proprietary technology platform to build a pipeline of …See details»
DICE Therapeutics - VentureRadar
Website: https://www.dicetherapeutics.com. Designs and develops innovative immunology therapies, focusing on creating convenient oral medicines with biologic-like efficacy for …See details»
Lilly strengthens autoimmune pipeline with Dice purchase
Jul 3, 2023 Eli Lilly and Company has announced that it will acquire Dice Therapeutics , a San Francisco–based biotech that develops oral drugs for chronic autoimmune and inflammatory …See details»
DICE Therapeutics - Overview, News & Similar companies
DICE Therapeutics contact info: Phone number: (650) 566-1402 Website: www.dicetherapeutics.com What does DICE Therapeutics do? DICE Therapeutics is a …See details»
Working at DICE Therapeutics - Glassdoor
DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis Oct 11, 2022 PDF Version Clinical proof-of-concept in …See details»
Contact Us – DICE THERAPEUTICS
Contact Us. 400 East Jamie Court Suite 300 South San Francisco CA 94080See details»
Lilly to Acquire DICE Therapeutics to Advance Innovation in …
Jun 20, 2023 INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and DICE Therapeutics, Inc. (NASDAQ: …See details»
DICE Therapeutics Inc. - Cruelty Free Investing
Dice Therapeutics, Inc., formerly Dice Molecules Holdings LLC, is a biopharmaceutical company. The Company leverages its technology platform to build a pipeline of oral therapeutic …See details»
Lilly to Acquire DICE Therapeutics to Advance Innovation in
Jun 20, 2023 INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., June 20, 2023/ PRNewswire/-- Eli Lilly and Company and DICE Therapeutics, Inc. today announced a …See details»
Approach - DICE THERAPEUTICS
Our approach to drug discovery and development leverages the capabilities of our DELSCAPE platform to optimize the design of small molecule therapeutics to modulate protein-protein …See details»
DICE Therapeutics Announces Pricing of Upsized Initial Public …
Sep 15, 2021 SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary …See details»
Careers - DICE THERAPEUTICS
Open Positions. At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient …See details»
DICE Therapeutics Announces Positive Topline Data from Phase 1 …
Oct 11, 2022 Clinical proof-of-concept in psoriasis patients achieved with a mean percentage reduction in PASI from baseline at 4 weeks of 43.7% in the high dose group compared to …See details»
Press Release - DICE THERAPEUTICS
DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis. View PDF. ARCHIVED PRESS RELEASES. Aug, 11 2022.See details»